Keros Therapeutics (NASDAQ:KROS) Rating Lowered to Neutral at Cantor Fitzgerald

Keros Therapeutics (NASDAQ:KROS) was downgraded by stock analysts at Cantor Fitzgerald from an “overweight” rating to a “neutral” rating in a report released on Tuesday, MarketBeat Ratings reports. Cantor Fitzgerald also issued estimates for Keros Therapeutics’ FY2025 earnings at ($5.82) EPS.

Other analysts also recently issued reports about the company. TD Cowen downgraded Keros Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Oppenheimer lowered their target price on Keros Therapeutics from $63.00 to $23.00 and set an “outperform” rating for the company in a research note on Thursday, January 16th. Wedbush lowered Keros Therapeutics from an “outperform” rating to a “neutral” rating and reduced their price target for the stock from $47.00 to $15.00 in a research report on Friday, January 17th. HC Wainwright lowered their price objective on shares of Keros Therapeutics from $100.00 to $47.00 and set a “buy” rating for the company in a research report on Friday, December 13th. Finally, BTIG Research cut shares of Keros Therapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday, December 12th. Six analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, Keros Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $52.56.

Keros Therapeutics Trading Down 0.2 %

Keros Therapeutics stock opened at $11.39 on Tuesday. The stock has a 50-day moving average price of $34.16 and a 200 day moving average price of $46.76. Keros Therapeutics has a 52 week low of $9.77 and a 52 week high of $73.00. The stock has a market cap of $461.41 million, a PE ratio of -2.19 and a beta of 1.43.

Keros Therapeutics (NASDAQ:KROS) last released its earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing the consensus estimate of ($1.28) by ($0.13). The business had revenue of $0.39 million for the quarter. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The company’s revenue for the quarter was up 4750.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.33) EPS. On average, equities analysts predict that Keros Therapeutics will post -4.74 EPS for the current year.

Hedge Funds Weigh In On Keros Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. KBC Group NV grew its stake in shares of Keros Therapeutics by 52.0% during the third quarter. KBC Group NV now owns 1,263 shares of the company’s stock valued at $73,000 after purchasing an additional 432 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Keros Therapeutics by 26.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock worth $77,000 after buying an additional 280 shares in the last quarter. Values First Advisors Inc. bought a new position in Keros Therapeutics in the 3rd quarter valued at $89,000. Point72 Asia Singapore Pte. Ltd. bought a new position in Keros Therapeutics in the 2nd quarter valued at $128,000. Finally, LMR Partners LLP acquired a new stake in shares of Keros Therapeutics in the 3rd quarter valued at $213,000. 71.56% of the stock is currently owned by institutional investors and hedge funds.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.